Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL215729 | 0.90 | PTGS2 (1.00) | PTGS2PTGS1 | |
| Sulfamide SCHEMBL4638353 | 0.89 | PTGS2 (0.80) | PTGS2PTGS1 | |
| SCHEMBL5069832 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5594782 | 0.87 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL214166 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5594101 | 0.86 | PTGS2 (0.80) | PTGS2PTGS1 | |
| SCHEMBL8292213 | 0.86 | PTGS2 (0.75) | PTGS2PTGS1 | |
| SCHEMBL27510699 | 0.86 | PTGS2 (0.75) | PTGS2PTGS1 | |
| SCHEMBL5594645 | 0.85 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL214744 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 324 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1479385-B1 | Use of cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia | SEARLE LLC (US) | 2008-07-02 | — | — | EP | claimed |
| CN-1332661-C | Methods of treating and preventing neoplasia using cyclooxygenase-2 inhibitors | SEARLE & CO (US) | 2007-08-22 | — | — | CN | claimed |
| EP-0843549-B1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A 4 HYDROLASE INHIBITOR | SEARLE & CO (US) | 2006-04-12 | — | — | EP | claimed |
| EP-0833622-B8 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | SEARLE & CO (US) | 2005-10-12 | — | — | EP | claimed |
| CN-1660083-A | Method of using benzenesulphoamides that are cyclooxygenase-2-inhibitors in the treatment and prevention of neoplasia | G D SIORL & CO (US) | 2005-08-31 | — | — | CN | claimed |
| EP-1539142-A2 | USE OF AN AMYLOID BETA VACCINATION IN COMBINATION WITH A SELECTIVE COX-2 INHIBITOR FOR THE TREATMENT OF ALZHEIMER S DISEASE | Pharmacia Corporation (US) | 2005-06-15 | — | — | EP | claimed |
| EP-1509224-A1 | METHODS USING A COMBINATION OF A 3-HETEROARYL-2-INDOLINONE AND A CYCLOOXYGENASE-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA | Pharmacia Corporation (US) | 2005-03-02 | — | — | EP | claimed |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | claimed |
| EP-1479385-A1 | Use of cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia | G.D. Searle LLC (US) | 2004-11-24 | — | — | EP | claimed |
| EP-1463500-A1 | USE OF COX-2 INHIBITORS IN COMBINATION WITH ANTIVIRAL AGENTS FOR THE TREATMENT OF PAPILLOMA VIRUS INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2004-10-06 | — | — | EP | claimed |
| WO-1998016227-A9 | METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE TREATMENT AND PREVENTION OF NEOPLASIA | — | 1998-07-30 | — | — | WO | claimed |
| EP-0843549-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A 4? HYDROLASE INHIBITOR | G.D. SEARLE & CO. (US) | 1998-05-27 | — | — | EP | claimed |
| WO-1998016227-A1 | METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE TREATMENT AND PREVENTION OF NEOPLASIA | G.D. SEARLE & CO. (US) | 1998-04-23 | — | — | WO | claimed |
| EP-0833622-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | G.D. SEARLE & CO. (US) | 1998-04-08 | — | — | EP | claimed |
| EP-0833664-A1 | COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B 4? RECEPTOR ANTAGONIST FOR THE TREATMENT OF INFLAMMATIONS | G.D. SEARLE & CO. (US) | 1998-04-08 | — | — | EP | claimed |
| EP-0772600-A1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-05-14 | — | — | EP | claimed |
| WO-1996041645-A1 | COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE B4 RECEPTOR ANTAGONIST FOR THE TREATMENT OF INFLAMMATIONS | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
| WO-1996041626-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
| WO-1996041625-A1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A4 HYDROLASE INHIBITOR | G.D. SEARLE & CO. (US) | 1996-12-27 | — | — | WO | claimed |
| WO-1996003388-A1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | PTGS2 1/4885PTGS1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.